NCT07115095 - Tumor Markers for Efficacy of Dual-Target Therapy in HER2+ Breast Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 1, 2021

Primary Completion Date

January 1, 2023

Study Completion Date

January 1, 2023

Conditions

HER2-positive Breast Cancer

Interventions

DRUG

TP Chemotherapy + Trastuzumab + Pertuzumab

Chemotherapy regimen: Paclitaxel (150 mg/m²) intravenously on Day 1 and Carboplatin (400 mg/m²) intravenously on Day 2. Targeted therapy: Trastuzumab (8 mg/kg) intravenously and Pertuzumab (initial dose 840 mg, subsequent doses 420 mg) intravenously. This regimen was repeated every 21 days for 6 cycles.

DRUG

TP Chemotherapy + Trastuzumab

Chemotherapy regimen: Paclitaxel (150 mg/m²) intravenously on Day 1 and Carboplatin (400 mg/m²) intravenously on Day 2. Targeted therapy: Trastuzumab (8 mg/kg) intravenously. This regimen was repeated every 21 days for 6 cycles.

Trial Locations (1)

710032

Xijing Hospital, Xi'an

All Listed Sponsors

lead

Nanlin Li

OTHER